New late-breaking data reinforce benefits of abbott's triclip™ for people with leaky tricuspid heart valve

Triluminate™ pivotal data presented at the american college of cardiology's annual scientific session (acc.25) and simultaneously published in circulation show the abbott triclip system reduces heart failure hospitalizations the latest results highlight significant improvements in tricuspid regurgitation and quality of life through two years abbott park, ill., march 31, 2025 /prnewswire/ -- abbott (nyse: abt) today announced late-breaking data from its triluminate™ pivotal trial that show the triclip™ transcatheter edge-to-edge repair (teer) system to treat tricuspid regurgitation (tr), or a leaky heart valve, offers substantial and sustained improvements in the severity of tr after two years.
ABT Ratings Summary
ABT Quant Ranking